Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn’s Disease

[1] Hanauer SB(2006)Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial Gastroenterology 130 323-333

[2] Sandborn WJ(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Lancet 359 1541-1549

[3] Rutgeerts P(1997)A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group N Engl J Med 337 1029-1035

[4] Hanauer SB(2004)Infliximab maintenance therapy for fistulizing Crohn’s disease N Engl J Med 350 876-885

[5] Feagan BG(2010)Infliximab, azathioprine, or combination therapy for Crohn’s disease N Engl J Med 362 1383-1395

[6] Lichtenstein GR(2008)Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study Gastroenterology 135 1493-1499

[7] Targan SR(2004)An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease Am J Gastroenterol 99 1984-1989

[8] Hanauer SB(2007)Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial Gut 56 1232-1239

[9] van Deventer SJ(2012)Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial Gastroenterology 142 1102-1111

[10] Sands BE(2009)Adalimumab for the treatment of fistulas in patients with Crohn’s disease Gut 58 940-948

[1] Hanauer SB(2006)Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial Gastroenterology 130 323-333

[2] Sandborn WJ(2002)Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial Lancet 359 1541-1549

[3] Rutgeerts P(1997)A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group N Engl J Med 337 1029-1035

[4] Hanauer SB(2004)Infliximab maintenance therapy for fistulizing Crohn’s disease N Engl J Med 350 876-885

[5] Feagan BG(2010)Infliximab, azathioprine, or combination therapy for Crohn’s disease N Engl J Med 362 1383-1395

[6] Lichtenstein GR(2008)Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study Gastroenterology 135 1493-1499

[7] Targan SR(2004)An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease Am J Gastroenterol 99 1984-1989

[8] Hanauer SB(2007)Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial Gut 56 1232-1239

[9] van Deventer SJ(2012)Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial Gastroenterology 142 1102-1111

[10] Sands BE(2009)Adalimumab for the treatment of fistulas in patients with Crohn’s disease Gut 58 940-948